Cannabidiol (CBD) in patients with mild to moderate symptoms of coronavirus 2019: a randomized, double-blind, placebo-controlled clinical trial

• Grant number: 20/12110-9
• Support Opportunities: Research Grants - Research in Public Policies
• Start date: March 01, 2021
• End date: February 28, 2023
• Field of knowledge: Health Sciences - Medicine - Psychiatry
• Agreement: CNPq - PPSUS
• Principal Investigator: José Alexandre de Souza Crippa
• Grantee: José Alexandre de Souza Crippa
• Host Institution: Faculdade de Medicina de Ribeirão Preto (FMRP). Universidade de São Paulo (USP). Ribeirão Preto , SP, Brazil
• Associated researchers: Alline Cristina de Campos ; Antonio Waldo Zuardi ; Flávia de Lima Osório ; Francisco Silveira Guimaraes ; Jaime Eduardo Cecilio Hallak

Abstract

The aim of this work is to conduct a randomized, double-blind, placebo-controlled clinical trial to assess the efficacy and safety of cannabidiol (CBD - 300 mg a day) in patients infected with SARS-CoV-2. The specific objectives are to assess whether, in patients with mild and moderate forms of SARS-CoV-2, daily use of CBD 300 mg for fourteen days is capable of: I) decrease viral load; II) modify inflammatory parameters, such as cytokines, measured from serum; II) reduceclinical and emotional symptoms through daily clinical evaluation; IV) improve the quality of life and sleep; V) reduce hospitalization and worsen the severity of the disease; v) Monitor the possible adverse effects of CBD use in these patients VI) Evaluate whether CBD 300 mg can prevent depression, burnout, PTSD and other neuropsychiatric disorders in SARS-CoV-2 patients; VII) Evaluate if CBD can prevent central structural and functional abnormalities in SARS-CoV-2 patients as assessed by DTI diffusion tensor imaging and rsfMRI - resting-state functional magnetic resonance imaging. (AU)

Scientific publications

(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)

SOUZA, JOSE DIOGO S.; ZUARDI, ANTONIO W.; GUIMARAES, FRANCISCO S.; OSORIO, FLAVIA DE LIMA; LOUREIRO, SONIA REGINA; CAMPOS, ALLINE CRISTINA; HALLAK, JAIME E. C.; DOS SANTOS, RAFAEL G.; MACHADO SILVEIRA, ISABELLA LARA; PEREIRA-LIMA, KARINA; et al. Maintained anxiolytic effects of cannabidiol after treatment discontinuation in healthcare workers during the COVID-19 pandemic. FRONTIERS IN PHARMACOLOGY, v. 13, p. 9-pg., 2022-10-03. (08/09009-2, 14/50891-1, 20/12110-9)

GUNASEKERA, BRANDON; DAVIES, CATHY; BLEST-HOPLEY, GRACE; VERONESE, MATTIA; RAMSEY, NICK F.; BOSSONG, MATTHIJS G.; RADUA, JOAQUIM; BHATTACHARYYA, SAGNIK; CBE CONSORTIUM. Task-independent acute effects of delta-9-tetrahydrocannabinol on human brain function and its relationship with cannabinoid receptor gene expression: A neuroimaging meta-regression analysis. NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS, v. 140, p. 22-pg., 2022-08-02. (20/12110-9, 20/12066-0)

CRIPPA, JOSE ALEXANDRE S.; ZUARDI, ANTONIO W.; GUIMARAES, FRANCISCO S.; CAMPOS, ALLINE CRISTINA; OSORIO, FLAVIA DE LIMA; LOUREIRO, SONIA REGINA; DOS SANTOS, RAFAEL G.; SOUZA, JOSE DIOGO S.; USHIROHIRA, JULIANA MAYUMI; PACHECO, JULIA COZAR; et al. Efficacy and Safety of Cannabidiol Plus Standard Care vs Standard Care Alone for the Treatment of Emotional Exhaustion and Burnout Among Frontline Health Care Workers During the COVID-19 Pandemic A Randomized Clinical Trial. JAMA NETWORK OPEN, v. 4, n. 8, AUG 13 2021. (08/09009-2, 20/12110-9)